Balyasny Asset Management
DMAC icon

Balyasny Asset Management’s DiaMedica Therapeutics DMAC Stock Holding History

Balyasny Asset Management’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,086
Closed -$136K – 3021
2025
Q4 		$136K Buy
+17,086
New +$128K ﹤0.01% 2934
2025
Q2 		– Sell
-25,270
Closed -$95.8K – 2937
2025
Q1 		$95.8K Buy
25,270
+10,689
+73% +$61.1K ﹤0.01% 2685
2024
Q4 		$79.2K Buy
+14,581
New +$68.8K ﹤0.01% 2620

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management's DMAC Position: Q1 2026 in Review

Balyasny Asset Management sold out of DiaMedica Therapeutics (DMAC) in Q1 2026, closing a stake of 17,086 shares — an estimated $136K sold.

Balyasny Asset Management first reported a position in DMAC in Q4 2024 and held it in 3 quarters. The position peaked at $136K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Balyasny Asset Management reported no remaining DiaMedica Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Balyasny Asset Management sold 17,086 DiaMedica Therapeutics shares in Q1 2026, an estimated $136K.
  • Balyasny Asset Management first reported a position in DiaMedica Therapeutics in Q4 2024 and held it in 3 quarters.
  • Balyasny Asset Management's DiaMedica Therapeutics position peaked at $136K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.